Increased serum interferon activity in sarcoidosis compared to that in tuberculosis: Implication for diagnosis?

• Published in: Heliyon Vol. 10; no. 18; p. e37103
• Main Authors: Schrijver, Benjamin, Göpfert, Jens, La Distia Nora, Rina, Putera, Ikhwanuliman, Nagtzaam, Nicole M.A.N., Smits te Nijenhuis, Marja A.W., van Rijswijk, Angelique L.C.T., ten Berge, Josianne C.E.M., van Laar, Jan A.M., van Hagen, P. Martin, Dik, Willem A.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 30.09.2024; Elsevier
• Subjects: Interferon; Interferon stimulated gene; Sarcoidosis; Tuberculosis; Uveitis; Interferon; Tuberculosis; Sarcoidosis; Interferon stimulated gene; Uveitis
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2024.e37103

In this study, we measured serum interferon (IFN) levels and activity in patients with sarcoidosis and tuberculosis (TB) with and without uveitis. We aimed to understand the role of IFN in the pathophysiology of both conditions and explore its potential as a discriminating marker for these clinically similar diseases. Sera from an Indonesian TB and a Dutch sarcoidosis cohort were used in the analysis. IFNα2 and IFNγ concentrations were measured using Simoa® and Luminex assays, respectively. Serum IFN activity was assessed by incubating THP-1 cells with patient serum and measuring IFN-stimulated gene transcription using qPCR. Anti-IFNα2 and IFNγ autoantibodies were detected via Luminex assay and tested for neutralizing capacity using a flow cytometry-based signal transducer and activator of transcription (STAT) 1 phosphorylation inhibition assay. IFNα2 was detected in 74 % and 64 % of patients with sarcoidosis and pulmonary TB, respectively, while IFNγ was found in 78 % and 23 % of patients with sarcoidosis and TB, respectively. For uveitis cases specifically, IFNα2 was detected in 85 % of sarcoid uveitis (SU) and 33 % of tubercular uveitis (TBU) cases. Similarly, IFNγ was detected in 69 % of SU and 17 % of TBU cases. IFNγ serum concentrations were higher in sarcoidosis than that in TB patients (p < 0.0001). Focusing on patients with uveitis, SU showed increased IFNα2 (p = 0.004) and IFNγ (p < 0.002) serum concentrations compared to that in TBU. Notably, TBU displayed significantly reduced IFNα2 concentrations compared to that in healthy controls (p = 0.006). These results align with the increased interferon stimulated gene (ISG) transcriptional upregulation observed in THP-1 cells stimulated with serum from patients with sarcoidosis. Elevated levels of non-neutralizing anti-IFN autoantibodies were observed in patients with TB; however, these levels were similar to those observed in geographically matched healthy Indonesian controls. Our results suggest decreased serum levels and activity of type I and II IFN in TB compared to those in sarcoidosis. This is indicative of distinct pathophysiological processes in these highly clinically similar diseases. We propose that the assessment of serum IFN levels and IFN activity has the potential to distinguish between sarcoidosis/SU and TB/TBU.